Chapter 1. COMPANION DIAGNOSTICS MARKET– Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. COMPANION DIAGNOSTICS MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. COMPANION DIAGNOSTICS MARKET– Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. COMPANION DIAGNOSTICS MARKET- Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. COMPANION DIAGNOSTICS MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. COMPANION DIAGNOSTICS MARKET– By Indications

6.1. Oncology

6.1.1. Colorectal Cancer

6.1.2. Lung Cancer

6.1.3. Breast Cancer

6.1.4. Gastric Cancer

6.1.5. Melanoma

6.2. Inflammation and Autoimmune Diseases

6.3. Cardiovascular Diseases

6.4. Central Nervous System Disorders

6.5. Virology Diseases

Chapter 7. COMPANION DIAGNOSTICS MARKET– By Technology

7.1. Immunohistochemistry

7.2. Molecular Diagnostics

7.2.1. In-Situ Hybridization

7.2.2. Real-Time PCR

7.2.3. Gene Sequencing

Chapter 8. COMPANION DIAGNOSTICS MARKET– By Region

8.1. North America

8.2. Europe

8.3.The Asia Pacific

8.4.Latin America

8.5. Middle-East and Africa

Chapter 9. COMPANION DIAGNOSTICS MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

9.1. Company 1

9.2. Company 2

9.3. Company 3

9.4. Company 4

9.5. Company 5

9.6. Company 6

9.7. Company 7

9.8. Company. 8

9.9. Company 9

9.10. Company 10